Correction to: Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease (Psychopharmacology, (2019), 236, 6, (1701-1715), 10.1007/s00213-018-5150-y)

Ajeesh Koshy Cherian; Aaron Kucinski; Ryan Wu; Inge E.M. de Jong; Martin Sarter

ArticleOPEN ACCESS

Correction to: Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease (Psychopharmacology, (2019), 236, 6, (1701-1715), 10.1007/s00213-018-5150-y)

Cherian A
Kucinski A
Wu R
et al.

Psychopharmacology

DOI: 10.1007/s00213-019-05375-0

0Citations

3Readers

Abstract

After publication of this paper, the authors determined that the “Acknowledgments” section was omitted. Below is the “Acknowledgments” statement.

Cite

CITATION STYLE

APA

Cherian, A. K., Kucinski, A., Wu, R., de Jong, I. E. M., & Sarter, M. (2020, January 1). Correction to: Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease (Psychopharmacology, (2019), 236, 6, (1701-1715), 10.1007/s00213-018-5150-y). Psychopharmacology. Springer. https://doi.org/10.1007/s00213-019-05375-0

Correction to: Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease (Psychopharmacology, (2019), 236, 6, (1701-1715), 10.1007/s00213-018-5150-y)

Abstract

Cite

Register to see more suggestions